Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

Merck’s Keytruda regimen succeeds in phase 3 NSCLC trial Merck’s Keytruda (pembrolizumab) in combination with pemetrexed (Alimta) plus platinum chemotherapy has significantly improved overall survival (OS) and progression-free survival (PFS) of certain type of lung cancer patients in a phase 3 trial. Contract Research & Services > Clinical Trials > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

ImmuPharma completes phase 3 trial of Lupus drug
ImmuPharma has completed its 52-week, randomised, double-blinded, phase 3 clinical trial of Lupuzor, its lead candidate for the potential breakthrough compound for Lupus.
Contract Research & Services > Clinical Trials > News
Merck’s Keytruda regimen succeeds in phase 3 NSCLC trial
By PBR Staff Writer
Merck’s Keytruda (pembrolizumab) in combination with pemetrexed (Alimta) plus platinum chemotherapy has significantly improved overall survival (OS) and progression-free survival (PFS) of certain type of lung cancer patients in a phase 3 trial.
Contract Research & Services > Clinical Trials > News

Contract Research

Charles River acquires UK CRO KWS BioTest
By PBR Staff Writer
Charles River Laboratories International has acquired UK-based contract research organization (CRO) KWS BioTest for about £15m.
Drug Research > Drug Delivery > News
Cue Biopharma forms research collaboration and signs license deal with Merck
Immunotherapy company Cue Biopharma has entered into a strategic research collaboration and license agreement with Merck.
Contract Research & Services > Contract Research > News

Contract Services

Arvinas, Genentech expand license agreement for Protac
Arvinas has expanded its ongoing license agreement with Genentech for the development of new therapeutics using its novel PROTAC technology.
Contract Research & Services > Contract Services > News
Xenetic signs sublicense deal related to PolyXen technology with Baxalta
Xenetic Biosciences has entered into a Right to Sublicense Agreement with Baxalta, Baxalta, and Baxalta (collectively, with their affiliates, “Baxalta”), wholly-owned subsidiaries of Shire.
Contract Research & Services > Contract Services > News